GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » Insider Ownership

Nuformix (LSE:NFX) Insider Ownership : 11.22 % (As of May. 06, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Nuformix Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nuformix's insider ownership is 11.22%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nuformix's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nuformix's Float Percentage Of Total Shares Outstanding is 0.00%.


Nuformix Insider Ownership Historical Data

The historical data trend for Nuformix's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix Insider Ownership Chart

Nuformix Historical Data

The historical data trend for Nuformix can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Insider Ownership 16.40 16.40 16.40 16.40 13.41 13.41 13.41 11.40 11.40 11.22

Nuformix Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Nuformix Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.